Intelligent Bio Solutions Inc (INBS)

Form 8-K - Current report

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Interference Study designed to validate system specificity in the presence of potentially interfering...

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the...

Form 8-K - Current report

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66...

Form 8-K - Current report

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the...

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances...

Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities